PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201)

被引：0

作者：

Hubbard, Joleen M.

Zemla, Tyler J.

Graham, Rondell P.

Jin, Zhaohui

Zhu, Mojun

Mitchell, Jessica L.

Novo, Elise

Vegh, Eva

Lorincz, Orsolya

Csiszovszki, Zsolt

Kremlitzka, Mariann

Somogyi, Eszter

Molnar, Levente

Toth, Jozsef

Toke, Eniko Rita

机构：

[1] Mayo Clin, Dept Med Oncol, Rochester, MN USA

[2] Mayo Clin, Rochester, MN USA

[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA

[4] Mayo Clin, Div Med Oncol, Rochester, MN USA

[5] St Laszlo Hosp, South Pest Ctr Hosp, Oncol, Budapest, Hungary

[6] TreosBio, Veszprem, Hungary

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3595

引用

页数：1

共 6 条

[1] Phase Ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC; OBERTO-201).
Hubbard, Joleen M.
Zemla, Tyler J.
Graham, Rondell P.
Jin, Zhaohui
Zhu, Mojun
Mitchell, Jessica L.
Novo, Elise
Vegh, Eva
Lorincz, Orsolya
Kremlitzka, Mariann
Somogyi, Eszter
Molnar, Levente
Toth, Jozsef
Toke, Eniko Rita
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 147 - 147
[2] A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Zhu, Mojun
Wittenberger, Kathleen
Csiszovszki, Zsolt
Somogyi, Eszter
Lorincz, Orsolya
Molnar, Levente
Toth, Jozsef
Youssoufian, Hagop
Toke, Eniko Rita
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301): Initial results
Hubbard, J.
Ahn, D.
Jones, J. C.
Jin, Z.
Zhu, M.
Xie, H.
Novo, E.
Graham, R.
Wittenberger, K.
Kremlitzka, M.
Csiszovszki, Z.
Somogyi, E.
Lorincz, O.
Molnar, L.
Toth, J.
Youssoufian, H.
Toke, E. R.
ANNALS OF ONCOLOGY, 2023, 34 : S452 - S452
[4] Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Wittenberger, Kathleen
Molnar, Levente
Lorincz, Orsolya
Somogyi, Eszter
Csiszovszki, Zsolt
Youssoufian, Hagop
Toke, Eniko Rita
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS283 - TPS283
[5] PolyPEPI1018 off-the shelf vaccine as add-on to maintenance therapy achieved durable treatment responses in patients with microsatellite-stable metastatic colorectal cancer patients (MSS mCRC)
Hubbard, Joleen
Cremolini, Chiara
Graham, Rondell
Moretto, Roberto
Mitchell, Jessica
Wessling, Jaclynn
Toke, Eniko
Csiszovszki, Zsolt
Lorincz, Orsolya
Molnar, Levente
Somogyi, Eszter
Megyesi, Monika
Pantya, Kata
Toth, Jozsef
Pales, Peter
Miklos, Istvan
Falcone, Alfredo
Hubbard, Joleen
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[6] Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
Desai, J.
Hong, Y. S.
Kim, J. E.
Kim, T. W.
Han, S. W.
Bang, Y-J.
Chee, C. E.
Heong, V. Y. M.
Mcree, A.
Chow, L. Q.
Kwak, E. L.
Infante, J. R.
Wallin, J.
Das Thakur, M.
Mwawasi, G.
Foster, P.
Cha, E.
Bendell, J. C.
ANNALS OF ONCOLOGY, 2016, 27

← 1 →